Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

BACKGROUND: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatm...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Respir Res
Main Authors: Marra, Alberto M., Halank, Michael, Benjamin, Nicola, Bossone, Eduardo, Cittadini, Antonio, Eichstaedt, Christina A., Egenlauf, Benjamin, Harutyunova, Satenik, Fischer, Christine, Gall, Henning, Ghofrani, Hossein Ardeschir, Hoeper, Marius M., Lange, Tobias J., Olsson, Karen M., Klose, Hans, Grünig, Ekkehard
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6299931/
https://ncbi.nlm.nih.gov/pubmed/30567595
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0957-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki